ES2058561T3 - Esteroides sustituidos con acido fosfonico como inhibidores de la esteroide-5alfa-reductasa. - Google Patents

Esteroides sustituidos con acido fosfonico como inhibidores de la esteroide-5alfa-reductasa.

Info

Publication number
ES2058561T3
ES2058561T3 ES89313264T ES89313264T ES2058561T3 ES 2058561 T3 ES2058561 T3 ES 2058561T3 ES 89313264 T ES89313264 T ES 89313264T ES 89313264 T ES89313264 T ES 89313264T ES 2058561 T3 ES2058561 T3 ES 2058561T3
Authority
ES
Spain
Prior art keywords
reductase
inhibitors
5alpha
steroid
phosphonic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89313264T
Other languages
English (en)
Inventor
Dennis Alan Holt
Mark Alan Levy
Brian Walter Metcalf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of ES2058561T3 publication Critical patent/ES2058561T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J61/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/002Expansion of ring A by one atom, e.g. A homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPONENTES DE ESTRUCTURA (I) EN EL QUE LAS LINEAS DOTADAS INDICAN LA PRESENCIA OPCIONAL DE ENLACES DOBLES E INTER ALIA Z ES (CH2)N DONDE N ES 0-2, R ES H, HIDROXI O ACETOXI, R1 ES H O AUSENTE Y R2 ESTA AUSENTE, H O CH3; PROCESOS PARA SU PREPARACION, COMPOSICIONES QUE LOS CONTIENEN Y SU USO EN MEDICINA COMO INHIBIDORES DE REDUCTASA-A-5.
ES89313264T 1988-12-23 1989-12-19 Esteroides sustituidos con acido fosfonico como inhibidores de la esteroide-5alfa-reductasa. Expired - Lifetime ES2058561T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/290,211 US4946834A (en) 1988-12-23 1988-12-23 Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors

Publications (1)

Publication Number Publication Date
ES2058561T3 true ES2058561T3 (es) 1994-11-01

Family

ID=23114990

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89313264T Expired - Lifetime ES2058561T3 (es) 1988-12-23 1989-12-19 Esteroides sustituidos con acido fosfonico como inhibidores de la esteroide-5alfa-reductasa.

Country Status (12)

Country Link
US (1) US4946834A (es)
EP (1) EP0375351B1 (es)
JP (1) JPH02215795A (es)
AT (1) ATE110736T1 (es)
AU (1) AU631387B2 (es)
CA (1) CA2005165A1 (es)
DE (1) DE68917885T2 (es)
DK (1) DK645289A (es)
ES (1) ES2058561T3 (es)
IE (1) IE65517B1 (es)
PT (1) PT92722A (es)
ZA (1) ZA899670B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026882A (en) * 1988-12-23 1991-06-25 Smithkline Beecham Corporation Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase
US4970204A (en) * 1989-08-23 1990-11-13 Smithkline Beecham Corporation 3-substituted nitro-steroid derivatives as 5-α-reductase inhibitors
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
IL104601A0 (en) * 1992-02-07 1993-07-08 Smithkline Beecham Corp Process for the preparation of steroidal dienes
DK0567271T3 (da) * 1992-04-20 1998-02-16 Sankyo Co Steroidderivater til behandling af prostatahypertrofi, fremgangsmåde til fremstilling heraf og anvendelser heraf
EP0641211A1 (en) * 1992-05-21 1995-03-08 Endorecherche Inc. INHIBITORS OF TESTOSTERONE 5$g(a)-REDUCTASE ACTIVITY
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5637310A (en) * 1993-12-20 1997-06-10 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
EP0754701B1 (en) * 1994-04-04 1998-08-12 Meiji Milk Products Company Limited Novel progesterone compound and use thereof
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
DE69942578D1 (de) 1998-05-22 2010-08-26 Univ R Bifunktionelle moleküle sowie darauf basierende therapien.
JP2000309599A (ja) 1999-04-13 2000-11-07 Kyowa Hakko Kogyo Co Ltd エストラ−1,3,5(10),16−テトラエン誘導体
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
NZ616673A (en) 2009-02-20 2014-08-29 To Bbb Holding B V Glutathione-based drug delivery system
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191759A (en) * 1978-04-13 1980-03-04 Merck & Co., Inc. N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4317817A (en) * 1979-08-27 1982-03-02 Richardson-Merrell Inc. Novel steroid 5α-reductase inhibitors
DK465481A (da) * 1980-11-21 1982-05-22 Hoffmann La Roche Fremgangsmaade til fremstilling af d-homostemoider
CA1252778A (en) * 1983-08-25 1989-04-18 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Steroids
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors

Also Published As

Publication number Publication date
DK645289A (da) 1990-06-24
EP0375351B1 (en) 1994-08-31
EP0375351A1 (en) 1990-06-27
DE68917885T2 (de) 1994-12-22
IE65517B1 (en) 1995-11-01
AU4700389A (en) 1990-06-28
CA2005165A1 (en) 1990-06-23
ZA899670B (en) 1990-11-28
US4946834A (en) 1990-08-07
DK645289D0 (da) 1989-12-19
PT92722A (pt) 1990-06-29
AU631387B2 (en) 1992-11-26
IE894110L (en) 1990-06-23
JPH02215795A (ja) 1990-08-28
ATE110736T1 (de) 1994-09-15
DE68917885D1 (de) 1994-10-06

Similar Documents

Publication Publication Date Title
ZA899671B (en) Phosphinic acid substituted steroids as inhibitors of steroid 5-alpha-reductase
ES2058561T3 (es) Esteroides sustituidos con acido fosfonico como inhibidores de la esteroide-5alfa-reductasa.
ES2067557T3 (es) Esteroides aromaticos sustituidos con acido fosfinico como inhibidores de la esteroide 5-d-reductasa.
ES2065400T3 (es) Esteroides aromaticos sustituidos con acidos fosfonicos como inhibidores de esteroide-5-alfa-reductasa.
NO905608D0 (no) Fremgangsmaate for fremstilling av a-nor-steroid-3-karboksylsyrederivater.
PT86652A (pt) Steroid 5-alpha-reductase inhibitors
ZA899669B (en) Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-alpha-reductase
FR2521995B1 (es)
ATE90355T1 (de) Weiche steroide mit anti-entzuendungswirkung.
PT86228A (de) Verfahren zur herstellung von 6alpha,9alpha-difluor-11beta,17alpha-dihydroxy-16alpha-methil-4-pregnen-3,20-dion und dessen derivate

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 375351

Country of ref document: ES